PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Center for Healthcare Organization and Implementation Research (CHOIR), Bedford VA Healthcare System, Bedford, Massachusetts, United States of America.\', \'Department of Mathematical Sciences, Bentley University, Waltham, Massachusetts, United States of America.\', \'Department of Public Health, Zuckerberg College of Health Sciences, University of Massachusetts Lowell, Lowell, Massachusetts, United States of America.\', \'Geriatric Research Education Clinical Center, Bedford VA Healthcare System, Bedford, Massachusetts, United States of America.\', \'Department of Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America.\', \'Department of Health Law, Policy and Management, Boston University School of Public Health, Boston, Massachusetts, United States of America.\', \'Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, Massachusetts, United States of America.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1371/journal.pone.0248652
?:doi
?:hasPublicationType
?:journal
  • PloS one
is ?:pmid of
?:pmid
?:pmid
  • 33735262
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.164
?:rankingScore_hIndex
  • 241
is ?:relation_isRelatedTo_publication of
?:title
  • The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all